Clinical trials: PAR
Hay Fever, Perennial Allergic Rhinitis
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.
- Trial name
- NCT00261287
- Testing
- Ciclesonide
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Healthy
Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg
The present study was conducted to find out whether the bioavailability of 0.25 mg pramipexole tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals was equivalent to the reference drug (Sifrol® tablet 0.25 mg…
- Trial name
- NCT02660060
- Testing
- Pramipexole Dexa Medica, Pramipexole Boehringer Ingelheim Pharma
- Where
- Indonesia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Rhinitis, Allergic, Perennial
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
- Trial name
- NCT01134705
- Testing
- Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
- Where
- 35 sites in United States
- Volunteers
- 474 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rhinitis Allergic
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
Primary Objective: To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after…
- Trial name
- NASANIF (NCT03317015)
- Testing
- triamcinolone XRG5029, fluticasone
- Volunteers
- 260 people
- Sponsor
- Sanofi
Rhinitis, Allergic, Perennial
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00103454
- Testing
- GW685698X
- Where
- 49 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus…
- Trial name
- NCT01401465
- Testing
- ciclesonide, mometasone
- Where
- 15 sites in United States
- Volunteers
- 327 people
- Sponsor
- Sumitomo Pharma America, Inc.
To Determine Bioequivalence Under Fed Conditions
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions
The purpose of this study is to compare the single-dose bioequivalence of Par and Oclassen doxycycline monohydrate 100 mg.
- Trial name
- NCT01380496
- Testing
- doxycycline monohydrate
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Perennial Allergic Rhinitis, Allergic Rhinitis
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Trial name
- NCT00163514
- Testing
- Ciclesonide
- Where
- 74 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Aortic Valve Disease
PAR I - Patient-to-Annulus Relation I
The Prosthesis-to-Annulus Relation I (PAR I) trial is a German multicenter study assessing the relation between the prosthetic GOA and the area of LVOT as potentially new parameter for the prediction of hemodynamic outcome.
- Trial name
- PARI (NCT02981004)
- Where
- 7 sites in Germany
- Volunteers
- 304 people
- Sponsor
- Abbott Medical Devices
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis Perennial
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244217
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 15 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Perennial Allergic Rhinitis (PAR)
Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
- Trial name
- NCT07890350
- Testing
- CM512
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Rhinitis, Allergic, Perennial
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with PAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00659750
- Testing
- Ciclesonide
- Where
- 23 sites in United States
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
Myopia, Dry Eye Disease (DED)
Study of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs
The goal of this observational study is to investigate the effects of eye fatigue induced by screen task on dry eye disease (DED) signs and symptoms, visual performance, and visual behavior in young adults with and without DED…
- Trial name
- RReye (NCT07844408)
- Testing
- Eye Exams, Ocular Biometry and Aberrometry, Wearing a Smartwatch
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Essilor International
Rhinitis, Allergic, Perennial
A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis
Allergic rhinitis is an IgE-mediated, inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial Allergic Rhinitis (PAR) starts in early childhood and occurs all year around.
- Trial name
- AVY-REG00108VN (NCT01270958)
- Testing
- Avamys aqueous nasal spray 110mcg
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Onychomycosis of Toenail
URGO MICKAEL Filmogel, Topical Treatment of Onychomycosis
The objective of this clinical study is to evaluate the performance of URGO MICKAEL Filmogel as a topical treatment for mild to moderate onychomycosis
- Trial name
- MICKAEL (NCT07828184)
- Testing
- URGO MICKAEL Filmogel
- Where
- France
- Volunteers
- 54 people
- Sponsor
- CEN Biotech
Perennial Allergic Rhinitis
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of…
- Trial name
- NCT01287364
- Testing
- ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
- Where
- 6 sites in United States
- Volunteers
- 185 people
- Sponsor
- Sumitomo Pharma America, Inc.
Perennial Allergic Rhinitis (PAR)
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
- Trial name
- NCT06339008
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 74 sites in United States, Belgium and 4 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company